101 related articles for article (PubMed ID: 19486027)
1. A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy.
Schiappoli M; Ridolo E; Senna G; Alesina R; Antonicelli L; Asero R; Costantino MT; Longo R; Musarra A; Nettis E; Crivellaro M; Savi E; Massolo A; Passalacqua G
Clin Exp Allergy; 2009 Oct; 39(10):1569-74. PubMed ID: 19486027
[TBL] [Abstract][Full Text] [Related]
2. Safety of immunotherapy with therapeutic vaccines containing depigmented and polymerized allergen extracts.
Casanovas M; Martín R; Jiménez C; Caballero R; Fernández-Caldas E
Clin Exp Allergy; 2007 Mar; 37(3):434-40. PubMed ID: 17359393
[TBL] [Abstract][Full Text] [Related]
3. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases.
Moreno C; Cuesta-Herranz J; Fernández-Távora L; Alvarez-Cuesta E;
Clin Exp Allergy; 2004 Apr; 34(4):527-31. PubMed ID: 15080803
[TBL] [Abstract][Full Text] [Related]
5. [New administration routes for immunotherapy].
Martorell Aragonés A
Allergol Immunopathol (Madr); 2000; 28(3):93-102. PubMed ID: 10867377
[TBL] [Abstract][Full Text] [Related]
6. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years.
Rienzo VD; Minelli M; Musarra A; Sambugaro R; Pecora S; Canonica WG; Passalacqua G
Clin Exp Allergy; 2005 May; 35(5):560-4. PubMed ID: 15898975
[TBL] [Abstract][Full Text] [Related]
7. Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts.
Casanovas M; Martín R; Jiménez C; Caballero R; Fernández-Caldas E
Int Arch Allergy Immunol; 2006; 139(2):153-8. PubMed ID: 16374026
[TBL] [Abstract][Full Text] [Related]
8. Side-effects of allergen-specific immunotherapy: a prospective multi-centre study.
Winther L; Arnved J; Malling HJ; Nolte H; Mosbech H
Clin Exp Allergy; 2006 Mar; 36(3):254-60. PubMed ID: 16499635
[TBL] [Abstract][Full Text] [Related]
9. Allergen immunotherapy-induced biphasic systemic reactions: incidence, characteristics, and outcome: a prospective study.
Confino-Cohen R; Goldberg A
Ann Allergy Asthma Immunol; 2010 Jan; 104(1):73-8. PubMed ID: 20143649
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of the pediatric aspects of the WHO document and meta-analysis of immunotherapy].
Ibáñez Sendín MD
Allergol Immunopathol (Madr); 2000; 28(3):82-9. PubMed ID: 10867375
[TBL] [Abstract][Full Text] [Related]
11. [Preventive immunotherapy].
Boquete M; Carballada F; Expósito F; González A
Allergol Immunopathol (Madr); 2000; 28(3):89-93. PubMed ID: 10867376
[TBL] [Abstract][Full Text] [Related]
12. The safety of allergen immunotherapy (IT) in Turkey.
Dursun AB; Sin BA; Oner F; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(2):123-8. PubMed ID: 16689186
[TBL] [Abstract][Full Text] [Related]
13. Nonfatal systemic allergic reactions induced by skin testing and immunotherapy.
Lin MS; Tanner E; Lynn J; Friday GA
Ann Allergy; 1993 Dec; 71(6):557-62. PubMed ID: 8267250
[TBL] [Abstract][Full Text] [Related]
14. Systemic reactions with aeroallergen cluster immunotherapy in a clinical practice.
Copenhaver CC; Parker A; Patch S
Ann Allergy Asthma Immunol; 2011 Nov; 107(5):441-7. PubMed ID: 22018617
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind, placebo-controlled study.
Mirone C; Albert F; Tosi A; Mocchetti F; Mosca S; Giorgino M; Pecora S; Parmiani S; Ortolani C
Clin Exp Allergy; 2004 Sep; 34(9):1408-14. PubMed ID: 15347374
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of allergen immunotherapy in the treatment of allergic rhinitis and asthma in real life.
Zeldin Y; Weiler Z; Magen E; Tiosano L; Kidon MI
Isr Med Assoc J; 2008 Dec; 10(12):869-72. PubMed ID: 19160945
[TBL] [Abstract][Full Text] [Related]
17. Analysis of an unusual cluster of systemic reactions to subcutaneous specific immunotherapy with respiratory allergens in one allergy center.
Scherer K; Schindler C; Arnold A; Bach S; Bircher AJ
Int Arch Allergy Immunol; 2012; 157(3):318-20. PubMed ID: 22056648
[TBL] [Abstract][Full Text] [Related]
18. Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations.
Ruëff F; Wolf H; Schnitker J; Ring J; Przybilla B
Allergy; 2004 Jun; 59(6):589-95. PubMed ID: 15147443
[TBL] [Abstract][Full Text] [Related]
19. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite.
Maestrelli P; Zanolla L; Pozzan M; Fabbri LM;
J Allergy Clin Immunol; 2004 Apr; 113(4):643-9. PubMed ID: 15100667
[TBL] [Abstract][Full Text] [Related]
20. Risk of systemic allergic reactions to allergen immunotherapy in a pediatric allergy clinic in Turkey.
Bahceci Erdem S; Nacaroglu HT; Karaman S; Unsal Karkıner CS; Gunay I; Dogan D; Asilsoy S; Altınoz S; Can D
Int J Pediatr Otorhinolaryngol; 2016 May; 84():55-60. PubMed ID: 27063754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
